The 11th International Congress on Targeted Anticancer Therapies, Paris,4-6 March 2013 (TAT 2013)

dc.contributor.author	Samoilenko, O.
dc.contributor.author	Zaletok, S.
dc.date.accessioned	2019-01-19T21:02:55Z
dc.date.available	2019-01-19T21:02:55Z
dc.date.issued	2013
dc.identifier.citation	The 11th International Congress on Targeted Anticancer Therapies, Paris,4-6 March 2013 (TAT 2013) / O. Samoilenko, S. Zaletok // Experimental Oncology. — 2013. — Т. 35, № 3. — С. 231-235. — англ.	uk_UA
dc.identifier.issn	1812-9269
dc.identifier.uri	http://dspace.nbuv.gov.ua/handle/123456789/145244
dc.description.abstract	A range of new and promising targeted drugs currently under development for improved cancer therapy were presented during the 11th International Congress on Targeted Anticancer Therapies, Paris, 4–6 March 2013 (TAT 2013). TAT 2013 was attended by over 500 participants from 46 countries. More than 60 plenary lectures and 70 posters, presented by leading experts in clinical cancer research and drug development, were devoted to dozens of emerging targeted agents and new drug targets under development for cancer therapy	uk_UA
dc.language.iso	en	uk_UA
dc.publisher	Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України	uk_UA
dc.relation.ispartof	Experimental Oncology
dc.subject	Chronicle	uk_UA
dc.title	The 11th International Congress on Targeted Anticancer Therapies, Paris,4-6 March 2013 (TAT 2013)	uk_UA
dc.type	Article	uk_UA
dc.status	published earlier	uk_UA